✦ LIBER ✦

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer

✍ Scribed by R. O’Connor; M. O’Leary; J. Ballot; C. D. Collins; P. Kinsella; D. E. Mager; R. D. Arnold; L. O’Driscoll; A. Larkin; S. Kennedy; D. Fennelly; M. Clynes; J. Crown

Publisher: Springer
Year: 2006
Tongue: English
Weight: 291 KB
Volume: 59
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0240-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of the

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

✍ StevenJ. Cohen; James Gallo; NancyL. Lewis; R.Katherine Alpaugh; Louis Gentner; 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 189 KB

A phase I and pharmacokinetic study of O

A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer

✍ A. R. Clamp; P. Schöffski; J. W. Valle; R. H. Wilson; S. Marreaud; A.-S. Govaert 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 315 KB

A phase I study of combination therapy w

A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer

✍ Manabu Shiozawa; Nobuhiro Sugano; Kazuhito Tsuchida; Soichiro Morinaga; Makoto A 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 296 KB

A phase I combination chemotherapy study

A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer

✍ Shuichi Hokita; Takashi Aikou; Futoshi Miyazono; Sumiya Ishigami; Kuniaki Aridom 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 201 KB

Pharmacokinetics of BW12C and mitomycin

Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer

✍ Ian F. Dennis; Jonathan R. S. Ramsay; Paul Workman; Norman M. Bleehen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 560 KB

Phase I and pharmacokinetic study of a l

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

✍ Francis J. Giles; Martin S. Tallman; Guillermo Garcia-Manero; Jorge E. Cortes; D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose